Person: ÇİMŞİT, CANAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ÇİMŞİT
First Name
CANAN
Name
6 results
Search Results
Now showing 1 - 6 of 6
Publication Open Access Diagnostic performance between RT-PCR and chest CT in outpatients with clinically suspected COVID-19(2023-08-01) TİGEN, ELİF; ERTÜRK ŞENGEL, BUKET; ÇİMŞİT, CANAN; APAYDIN KAYA, MEMNUNE ÇİĞDEM; KORTEN, VOLKAN; TİGEN E., ERTÜRK ŞENGEL B., ÇİMŞİT C., PERK GURUN H., APAYDIN KAYA M. Ç., KORTEN V.Objective: To investigate the diagnostic performance between chest computed tomography (CT) and reverse transcription-polymerase chain reaction (RT-PCR) in outpatients with suspected coronavirus disease 2019 (COVID-19). Patients and Methods: Between March and June 2020, a total of 812 patients with clinically suspected COVID-19 who underwent both chest CT and initial-single RT-PCR on admission to outpatient units were retrospectively enrolled. CT severity-score (CT-SS) was calculated and data were matched with PCR results. Results: Of 812 patients, 54% (439/812) had positive RT-PCR results, and 47% (425/812) had a positive chest CT scan. With RT-PCR results as reference, the sensitivity, specificity, accuracy of chest CT in defining COVID-19 infection were 60%, (95% CI 56-65%, 265/439 patients), 57% (95% CI 52-62%, 213/373), 59% (95% CI 55-62%, 478/812), respectively. Three hundred eighty-seven (47%) patients had no CT findings, 380/812 (46.8%) had mild, 45/812 (5.5%) had moderate, and no patients in the severe group Conclusion: Chest CT did not show high sensitivity for the diagnosis of COVID-19 for outpatients. We suggest RT-PCR should be the primary diagnostic tool. Chest CT might be considered if there is a strong clinical suspicion with repeatedly negative RT-PCR test results, ensuring infection prevention and control measures can be preserved.Publication Open Access Radiation pneumonitis in relation to pulmonary function, dosimetric factors, TGFβ1 expression, and quality of life in breast cancer patients receiving post-operative radiotherapy: a prospective 6-month follow-up study.(2022-12-08) ÇİMŞİT, CANAN; Ozgen Z., Orun O., Atasoy B. M., Mega Tiber P., Akdeniz E., Cimsit C., Eryuksel E., Karakurt S.Purpose To investigate development of radiation pneumonitis (RP) in relation to pulmonary function, dosimetric factors, and transforming growth factor beta-1 (TGFβ1) expression in irradiated breast cancer patients. Methods A total of 49 breast cancer patients who received post-operative radiotherapy (RT) were evaluated in terms of pulmonary function tests (PFTs), quality of life (QoL), development of RP, dosimetric factors, cytokine levels, and lung highresolution computed tomography (HRCT) before and after RT. ROC analysis was performed for performance of dosimetric factors in predicting RP, while frequencies of single nucleotide polymorphisms (SNPs) genotyped for TGFβ1 (rs11466345 and rs1800470) were also evaluated. Results All cases with RP (10.2%) recovered clinically at the end of third post-RT month. PFT and HRCT parameters were similar before and after RT overall, as well as by RP and the radiation feld subgroups. ROC analysis revealed the signifcant role of the ipsilateral V5 (cutof value of 45.9%, p=0.039), V10 (29.4%, p=0.015), V20 (23%, p=0.017), and MLD (1200 cGy, p=0.030) in predicting RP. Higher post-RT TGFβ1 levels (p=0.037) were noted overall and in patients with RP. Patient and control groups were similar in terms of frequencies of SNPs genotyped for TGFβ1 (rs11466345 and rs1800470). EORTC QLQ-C30 and QLQ-BR-23 scores were similar in patients with vs. without RP. Conclusion Our fndings revealed signifcant role of dosimetric factors including MLD, V20 as well as the low dose-volume metrics in predicting the risk of RP among breast cancer patients who received post-operative RT. Implementation of RT, extent of radiation feld or the presence of RP had no signifcant impact on PFTsPublication Open Access Radiological quantification of sarcopenic obesity and its role in chronic liver disease severity(2023-04-01) ÇİMŞİT, CANAN; KURŞUN, MELTEM; DEMİRCİOĞLU, ÖZLEM; GÜNDÜZ, FEYZA; DEMİRTAŞ, COŞKUN ÖZER; Çimşit C., Kurşun M., Demircioğlu Ö., Dilber F., Demirtaş C. Ö., Ergenç İ.Publication Open Access Radiological comparison of the Wuhan and B.1.1.7 variant COVID-19 infection; are there any differences in chest CT scans(2022-07-01) DEMİRCİOĞLU, ÖZLEM; KOCAKAYA, DERYA; ÇİMŞİT, CANAN; ÜLGER, NURVER; ÇİMŞİT, NURİ ÇAGATAY; DEMİRCİOĞLU Ö., KOCAKAYA D., ÇİMŞİT C., CAN SARINOĞLU R., ÜLGER N., ÇİMŞİT N. Ç.Aim: In September 2020, a variant of the SARS-CoV-2 virus was detected in England and it became the dominant type in most of the countries. The clinical behavior of the B.1.1.7 variant COVID-19 infectionis different from the Wuhan type.So we aimed to investigate whether there are any differences in computed tomography (CT) imaging findings of pneumonia caused by COVID-19 variants. Material and Method: 340 patients who admitted to the emergency departmentwith symptoms of dyspnea and chest pain suspecting COVID-19 pneumonia and pulmonary embolism were included in the study. Oncology (n:12) and pediatric (n:8) patients, patients with negative PCR test (n:56), and patients infected with different variant (n:6) were excluded leaving 258 patients grouped into two (B.1.1.7 and Wuhan type) for evaluation of CT findings such as pleural thickening,pleural and pericardial effusion, consolidation, GGO presence and distribution, upper lobe involvement, pulmonary embolism, tree in bud pattern, centrilobuler nodule, revers halo sign, and hepatosteatosis. Results: A statistically significant difference was obtained between the two groups in terms of pleural thickening (p=0.020), upper lobe involvement (p=0.037), localization of GGO (p=0.001), presence of pleural effusion (p=0.025), embolism (p=0.011) and presence of consolidation (p=0.042). However, no significant difference was found for the development of hepatosteatosis (p=0.520). Conclusion: There aredifferences in radiological findings between B.1.1.7 variant and Wuhan type. In our study atypical radiological findings are more common in B.1.1.7 type. In addition, radiological findings that seen in severe COVID-19 pneumonia are more common in B.1.1.7.Publication Open Access Computed Tomography-Assessed Sarcopenia Predicts Mortality in Kidney Transplant Candidates(2024-03-01) KURŞUN, MELTEM; ÇİMŞİT, CANAN; Coban H., Atas D. B., Tugcu M., KURŞUN M., ÇİMŞİT C., Asicioglu E., Arikan H., Tuglular S., Velioglu A.Objectives: Sarcopenia is common in chronic kidney disease and associated with increased mortality. We investigated the prevalence of sarcopenia, defined as low muscle mass by the psoas muscle index, in end-stage renal disease patients on waiting lists for kidney transplant and determined its association with prognostic nutritional index, C-reactive protein-to-albumin ratio, cardiovascular events, and mortality. Materials and Methods: Our study included 162 patients with end-stage renal disease and 87 age-matched healthy controls. We calculated nutritional status as follows: prognostic nutritional index = (10 × albumin [g/dL]) + (0.005 × total lymphocyte count (×103/μL]) and C-reactive protein-to-albumin ratio. We gathered demographic and laboratory data from medical records. Results: Patients with end-stage renal disease had a mean age of 44.7 ± 14.2 years; follow-up time was 3.37 years (range, 0.35-9.60 y). Although patients with end-stage renal disease versus controls had higher prevalence of sarcopenia (16.7% vs 3.4%; P =.002) and C-reactive protein-to-albumin ratio (1.47 [range, 0.12-37.10] vs 0.74 [range, 0.21-10.20]; P <.001), prognostic nutritional index was lower (40 [range, 20.4-52.2] vs 44 [range, 36.1-53.0]; P <.001). In patients with end-stage renal disease with and without sarcopenia, prognostic nutritional index (P =.005) was lower and C-reactive protein-to-albumin ratio (P =.041) was higher in those with versus those without sarcopenia. Among 67 patients on waiting lists who received kidney transplants, those without sarcopenia had better 5-year patient survival posttransplant than those with sarcopenia (P =.001). Multivariate regression analysis showed sarcopenia and low prognostic nutritional index were independent risk factors for mortality among patients with end-stage renal disease. Conclusions: Sarcopenia was ~5 times more frequent in patients with end-stage renal disease than in healthy controls and was positively correlated with the prognostic nutritional index. Sarcopenia was an independent risk factor for mortality in patients on transplant waiting lists.Publication Open Access Sarcopenia predicts mortality in renal transplant candidates(2022-05-01) BARUTÇU ATAŞ, DİLEK; ARIKAN, İZZET HAKKI; ÇOBAN, HARUN; AŞICIOĞLU, EBRU; ÇİMŞİT, CANAN; VELİOĞLU, ARZU; TUĞCU, MURAT; TUĞLULAR, ZÜBEYDE SERHAN; KURŞUN, MELTEM; ÇOBAN H., BARUTÇU ATAŞ D., KURŞUN M., TUĞCU M., AŞICIOĞLU E., ARIKAN İ. H., Cimsit C., TUĞLULAR Z. S., VELİOĞLU A.BACKGROUND AND AIMS: Sarcopenia is common in chronic kidney disease (CKD) and is associated with increased mortality and morbidity. Sarcopenia in CKD can be defined as a decreased muscle mass, mainly due to the catabolic state caused by the uremic environment. Malnutrition and inflammation are also common in sarcopenic patients. In this study, we aimed to investigate the prevalence of sarcopenia defined as low muscle mass determined by Psoas Muscle Index (PMI) in waitlisted end-stage renal disease (ESRD) patients and its association between ‘Prognostic Nutritional Index (PNI)’, ‘C-reactive protein (CRP) to Albumin Ratio (CAR)’ and mortality. METHOD: ESRD patients registered to national kidney transplant waiting list and had abdomen CT at admission were included in the study. Kidney donor candidates were constituted as healthy controls. PMI (cm2/m2) were calculated by proportioning the psoas muscle area detected in the abdomen CT with the square of the height. The PMI of the controls at the fifth percentile according to gender was accepted as the limit value for sarcopenia. PNI and CAR were calculated using albumin, CRP and absolute lymphocyte count. The associations between PMI, PNI, CAR and all-cause mortality were investigated. RESULTS: A total of 162 ESRD patients and 87 age matched healthy controls were included in the study. The mean age of the patients was 44.7 ± 14.2 years and followup time was 3.37 (0.35–9.60) years. The mean PMI were similar between the groups (5.24 ± 1.71 versus 5.48 ± 1.87 cm2/m2, P = 0.302). While prevalence of sarcopenia (16.7% versus 3.4%, P = 0.002) and CAR [1.47 (0.12–37.10) versus 0.74 (0.21–10.20), P < 0.001] was higher; PNI [40 (20.4–52.2) versus 44 (36.1–53.0), P < 0.001] was lower in ESRD patients than controls. When ESRD patients compared according to sarcopenia PMI [3.45 ± 0.9 versus 5.59 ± 1.6, P < 0.001] and PNI [39 (20.4–51) versus 41 (23–52.2), P = 0.005] was significantly lower and CAR [2.03 (0.28–34.65) versus 1.28 (0.12–37.1), P = 0.041] was higher in sarcopenic ESRD group than nonsarcopenic ESRD group (Table 1). In the correlation analysis, PMI was positively correlated with PNI (r = 0.246, P = 0.002), no correlated with CAR (r = −0.061, P = 0.445). In the follow-up, 67 waitlisted patients had been transplanted. In the five-year survival analysis, the non-sarcopenic transplant group [95% CI: 4.612–5.123 versus 95% CI: 2.721–5.413, P = 0.001] had better survival than sarcopenic transplant group (Figure 1). Mortality rates were similar in both sarcopenic transplant group and non-sarcopenic-non-transplant group. Multivariate regression analysis showed that sarcopenia (HR: 10.277, 95% CI: 3.912–27.000, P < 0.001), not having a transplant (HR: 3.949, 95% CI: 1.301–11.993, P = 0.015), low PNI (HR: 3.532, 95% CI: 1.303– 9.574, P = 0.013) and duration of renal replacement therapy (HR: 1.009, 95% CI: 1.002–1.015, P = 0.008) were independent risk factors for mortality in all ESRD group. CONCLUSION: In this study we observed that sarcopenia, as defined by low muscle mass, is almost seen five times more frequent in ESRD patients than controls and positively correlated wit